oxycodone Side Effects
Also known as: OxyContin, Roxicodone
Analysis of 180,422 adverse event reports submitted to the FDA from 2002 to 2025.
Total Reports
180,422
Death-Related
51,490
28.5% of reports
Hospitalizations
49,832
27.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 51,490 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 19,545 |
| TOXICITY TO VARIOUS AGENTS | 13,662 |
| OVERDOSE | 8,264 |
| DRUG ABUSE | 5,138 |
| COMPLETED SUICIDE | 3,586 |
| OFF LABEL USE | 2,585 |
| PAIN | 2,220 |
| FATIGUE | 2,158 |
| DRUG DEPENDENCE | 2,137 |
| VOMITING | 1,984 |
| RASH | 1,913 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,906 |
| PNEUMONIA | 1,880 |
| NAUSEA | 1,781 |
| HYPERTENSION | 1,776 |
| INFUSION RELATED REACTION | 1,759 |
| DIARRHOEA | 1,757 |
| RHEUMATOID ARTHRITIS | 1,753 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 1,750 |
| TYPE 2 DIABETES MELLITUS | 1,748 |
Reactions in Hospitalization Reports
Top reactions in 49,832 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PAIN | 5,123 |
| FATIGUE | 4,805 |
| NAUSEA | 4,647 |
| VOMITING | 4,119 |
| DIARRHOEA | 4,074 |
| DYSPNOEA | 4,068 |
| PNEUMONIA | 3,998 |
| OFF LABEL USE | 3,975 |
| PYREXIA | 3,631 |
| DRUG INEFFECTIVE | 3,437 |
| CONFUSIONAL STATE | 3,328 |
| ARTHRALGIA | 3,299 |
| RASH | 3,254 |
| HEADACHE | 3,038 |
| ASTHENIA | 3,002 |
| MALAISE | 2,810 |
| TOXICITY TO VARIOUS AGENTS | 2,708 |
| FALL | 2,705 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 2,705 |
| CONDITION AGGRAVATED | 2,701 |
Nearby — Related Medications
What the FAERS Data Reveals About oxycodone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 180,422 voluntary reports linked to oxycodone and its brand equivalents (OxyContin, Roxicodone), spanning 2002 through 2025. Of those, 51,490 (28.5%) listed death as an outcome and 49,832 (27.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 54% were female and 46% male; age distribution skews toward 45-64, with 36,952 reports in that bracket. The single most reported reaction is drug dependence with 27,480 submissions, followed by pain and death.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.